EQT Life Sciences Drives Innovation in Maternal Health by Funding Nua Surgical's C-Section Device

Series A Funding for Nua Surgical's C-Section Device

EQT Life Sciences has recently announced a significant advancement in maternal health by leading a €6.5 million Series A funding round for Nua Surgical, a pioneering Irish medical device company. This funding aims to propel the commercialization of SteriCISION, a groundbreaking device specifically designed for Caesarean sections (C-sections).

C-sections are not just common; they represent the most frequently performed major surgical procedure worldwide, with more than 30 million conducted each year. The SteriCISION C-Section Retractor stands out as the first self-retaining surgical retractor made exclusively to tackle the unique challenges faced during this type of surgery.

Innovative Design for Better Health Outcomes

The SteriCISION device is ergonomically crafted to provide fast, adjustable, and effective retraction for clinicians. It enables greater visibility during surgery, vital for safely delivering the baby, repairing tissues, and identifying any potential bleeding. The single-use sterile nature of SteriCISION helps in minimizing the risk of surgical complications, ultimately benefiting not just patients, but also healthcare professionals and the broader healthcare system.

This investment is set to accelerate Nua Surgical's journey toward early commercialization and fulfill regulatory requirements, including gaining FDA clearance. Furthermore, the funds will facilitate the expansion of the company’s team and establish manufacturing capabilities in Ireland.

Barry McCann, the CEO of Nua Surgical, expressed excitement regarding the funding, stating, "Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides us the capital needed for product advancement but also brings us seasoned investors who align with our vision to redefine maternal healthcare.”

The Future of Maternal Health

The support from EQT Life Sciences and other investors such as Kidron Capital, Texas Medical Center (TMC) Venture Fund, and existing backers like Enterprise Ireland, marks an important collaborative effort aimed at enhancing the safety and efficacy of C-section surgeries. Anne Portwich, a Partner at EQT, emphasized that the SteriCISION C-Section Retractor could potentially enhance outcomes for mothers during these procedures.

With the completion of this funding round, EQT and Kidron Capital will not only inject capital but will also gain a seat on the Nua Surgical Board of Directors, aiming to guide the company's strategic growth. Additional board positions will feature representatives from TMC Venture Fund and EQT as Board Observers.

As the healthcare sector continues to evolve, investments like these signify a positive trend towards innovative medical solutions that address real-world challenges. Nua Surgical aims to not just improve surgical outcomes, but to transform the field of maternal health with advancements like the SteriCISION retractor.

This funding launch marks an exciting new chapter for Nua Surgical and promises to bring forth innovative products designed to enhance care for mothers and their newborns, ultimately leading to improved healthcare standards around the globe.